Siderophore-conjugated monocarbams (AstraZeneca)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSiderophore-conjugated monocarbams (AstraZeneca)
Drug Alias NamePBP3 inhibitors (AstraZeneca)penicillin-binding protein 3 inhibitors (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPenicillin-binding protein 3 inhibitors
TargetsPenicillin-binding protein 3
Therapy Area/IndicationsMultidrug-Resistant InfectionPseudomonas Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsMultidrug-Resistant InfectionPseudomonas Infections

Other Information

ATC CodeN/A
Related LinksN/A